Komori
KYORIN Pharmaceutical (4569) · RiskMitigated

Deterioration in Business Results Due to Product Recalls

First written in FY2017. 2 of 6 entries say "Restated". Latest entry: FY2020-Q3.

6entries
4years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseFirst statedFY2017 – FY2018MaterialisedFY2019-Q3 – FY20192017: 120172018: 120182019: 320192020: 12020
Same theme, other companies
Impact on Trust and Business Performance from Product Safety and Quality IssuesA theme 52 companies write about · 52 as a headwind · 0 as a tailwind

The whole theme swung hardest in 2026: 2 of 7 companies on the "Worse" side.

11 other companies' latest entry also says "Mitigated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 52 companies compared. The sentences above are computed from all 52.
Full recordFilings, disclosures and news, newest first
  1. FY2020-Q3MitigatedAnnual report

    「Desalex, a long-acting selective H1 receptor antagonist and allergy treatment, supply of which resumed in November of the same year」

    Supply of Desalex was resumed in November 2019 following its suspension due to the voluntary recall.
  2. FY2020-Q2RestatedAnnual report

    「Impact of the temporary supply suspension of Desalex, a long-acting selective H1 receptor antagonist and allergy treatment」

    The supply suspension of Desalex continued to affect results this quarter as an actual product-recall and supply risk.
  3. FY2019MaterialisedAnnual report

    「Following MSD Co., Ltd., the marketing authorization holder, deciding to conduct a voluntary recall, 杏林製薬㈱, the distributor, has been recalling the product since 7 January 2019.」

    A voluntary recall of Desalex was decided on, and the distributor began the recall on 7 January 2019.
  4. FY2019-Q3MaterialisedAnnual report

    「With MSD Co., Ltd., the marketing authorization holder for Desalex, a sustained-release H1 receptor antagonist and treatment for allergic diseases, deciding to conduct a voluntary recall, 杏林製薬㈱, the distributor, has been recalling the product since 7 January 2019.」

    The product recall risk materialized in the form of MSD's decision to conduct a voluntary recall of Desalex and 杏林製薬㈱'s recall beginning on 7 January 2019.
  5. FY2018RestatedAnnual report

    「If defects are identified in Group products due to contamination or other causes, resulting in product recalls or similar events, this will adversely affect business results and other performance indicators.」

    The risk of recalls due to product defects or foreign matter contamination continues to be disclosed.
  6. FY2017First statedAnnual report

    「If defects are identified in Group products due to contamination or other causes, resulting in product recalls or similar events, this will adversely affect business results and other performance indicators.」

    Product defects or contamination leading to recalls are identified as risks that could adversely affect business results.
Moved together

"Decline in Upfront License Fees and Royalty Income" moved the same way as this thread, in the same document, in 3 of its 6 moves.

3222★1234
  1. ★This thread
  2. 1Decline in Upfront License Fees and Royalty Income3×
  3. 2Building a Core Business within the Healthcare Business2×
  4. 3Acquiring Exclusive Distribution Rights for Desloratadine2×
  5. 4KRP-AM1977X Marketing Authorization Application2×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
No upcoming earnings preview for KYORIN Pharmaceutical yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.